Stefan Beissert
Dresden, SN, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 151 publications
Corneal tomography detection of elevated ectasia risk in atopic dermatitis patients with no prior ophthalmologic diagnosis.
Journal: Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
Published: July 14, 2026
Correction: 1H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.
Journal: Scientific reports
Published: July 08, 2026
Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro.
Journal: Oncology letters
Published: June 22, 2026
Quantifying the Interplay Between PRAME Expression and Classical Morphology: A Multivariable Analysis of 954 Suspected Melanocytic Lesions.
Journal: Dermatopathology (Basel, Switzerland)
Published: June 18, 2026
Earlier detection of melanoma using in vivo reflectance confocal microscopy-a retrospective analysis.
Journal: Frontiers in medicine
Published: March 09, 2026
Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: November 14, 2025
Evaluating Risankizumab's Long-Term Effects in Psoriasis Using Optical Coherence Tomography.
Journal: Dermatology and therapy
Published: October 01, 2025
Line-Field Confocal Optical Coherence Tomography Criteria of Hair Follicles in Patients with Hidradenitis Suppurativa versus Healthy Controls.
Journal: Dermatology (Basel, Switzerland)
Published: August 24, 2025
Long-Term Efficacy and Safety of Secukinumab in Children and Adolescents with Moderate-to-Severe Chronic Plaque Psoriasis: Four-Year Results of a Randomized, Phase III, Open-Label Trial.
Journal: Paediatric drugs
Published: July 30, 2025
Dupilumab in patients with bullous pemphigoid and concomitant atopy.
Journal: Frontiers in pharmacology
Published: June 29, 2025
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.
Journal: American journal of clinical dermatology
Published: June 23, 2025
Last Updated: 09/26/2026